Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who ...

A federal jury Tuesday handed Gilead Sciences Inc. a victory against the U.S. government in a long, contentious battle over control of three patents for two important HIV-fighting drugs. The verdict ...

Because Truvada and Descovy already exist as effective PrEP options, it was considered unethical to include a placebo group. Zero cases of HIV infection were reported among women in the lenacapavir ...

As Gilead Sciences tussles with a web of HIV drug litigation, a high-stakes case tied to patents for prevention medicines is coming back to test the drugmaker. On Friday, the U.S. Department of ...

May 9 (Reuters) - A federal jury on Tuesday found that Gilead Sciences Inc (GILD.O), opens new tab did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on ...